Taris Biomedical

GPTKB entity

Properties (66)
Predicate Object
gptkbp:instanceOf gptkb:Company
gptkbp:acquisition Acquired_by_UroGen_Pharma_in_2020
gptkbp:advertising Targeted therapies
gptkbp:businessModel Biopharmaceutical development
gptkbp:CEO gptkb:Dr._Michael_A._D._Dyer
gptkbp:clinicalTrials Oncology
Phase 2
Phase 3
Ongoing studies
Patient recruitment
Multicenter studies
Quality of life studies
Phase 1 studies
Long-term follow-up studies
Real-world evidence studies
Efficacy trials
Non-muscle invasive bladder cancer
Patient outcomes assessment
Safety and efficacy studies
Survival studies
Biomarker_studies
gptkbp:collaborations Academic institutions
Industry partners
gptkbp:employeeCount 50-100
gptkbp:focus Urology
gptkbp:founded 2013
gptkbp:founder gptkb:Dr._David_A._Kessler
gptkbp:funding Venture capital
gptkbp:headquarters gptkb:Durham,_North_Carolina
https://www.w3.org/2000/01/rdf-schema#label Taris Biomedical
gptkbp:industry Biotechnology
gptkbp:innovation Advanced drug formulations
gptkbp:investmentFocus $30 million
Series B
gptkbp:leadership Experienced management team
gptkbp:mission Improve patient outcomes
gptkbp:partnerships gptkb:UroGen_Pharma
Pharmaceutical companies
Research collaborations
Clinical research organizations
Healthcare_providers
gptkbp:patentCitation Drug delivery technology
gptkbp:products gptkb:TARIS™_Bladder_Drug_Delivery_System
gptkb:TARIS™_Platform
UroGen
UroGen's_Jelmyto
UroGen's_UGN-101
UroGen's_UGN-102
UroGen's_UGN-201
UroGen's_UGN-202
UroGen's_UGN-203
UroGen's_UGN-204
gptkbp:regulatoryBody gptkb:FDA
gptkbp:regulatoryCompliance FDA_approval
gptkbp:research_areas Drug development
Translational medicine
Urological diseases
Oncology therapeutics
gptkbp:research_focus Patient-centered care
Innovative therapies
Localized therapy
gptkbp:targetMarket gptkb:Bladder_cancer
gptkbp:technology Drug delivery system
Nanoparticle delivery system
Biodegradable_polymers
gptkbp:website www.tarisbiomedical.com